Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Eisai, Keio Univ. Seal 10-Year Collaboration on Dementia Research
December 26, 2016
- Ono In-Licenses OmniAb Antibody Producing Platforms from US Biotech
December 26, 2016
- Chugai Licenses Marine-Derived Cancer Med from Spain’s PharmaMar
December 26, 2016
- Hemophilia Med Emicizumab Hits PIII Target; Global Filings Slated for 2017
December 26, 2016
- Keytruda Filed for Hodgkin’s Lymphoma, 3rd Indication in Japan
December 26, 2016
- Sawai Prevails in Patent Suit over Elplat
December 26, 2016
- New Indication Added to Plavix Generics to Fill Gap with Originator
December 22, 2016
- Janssen’s MM Med Daratumumab Filed in Japan
December 22, 2016
- Sumitomo Dainippon to Buy US Hematology Startup Tolero
December 22, 2016
- Otsuka, Akebia Form US Collaboration on Anemia Med Vadadustat
December 22, 2016
- Astellas Completes Acquisition of Ganymed
December 22, 2016
- Ono Slashes Opdivo Sales Outlook on 50% Price Cut
December 22, 2016
- NEC Ventures into AI-Based Drug Discovery Biz
December 21, 2016
- Astellas’ DNA Vaccine for Peanut Allergy Granted FDA Fast-Track Status
December 21, 2016
- Tagrisso Logs Significant PFS Extension in Japanese NSCLC Patients
December 21, 2016
- Osteoporosis Med Romosozumab Filed in Japan for High-Risk Patients
December 21, 2016
- Nippon Shinyaku Gets Japan Rights to Danish Firm’s Iron Deficiency Med
December 21, 2016
- Teijin Pharma, Amgen Ink License Pact on Kidney Diseases
December 21, 2016
- New Technologies to Cure Cancers, Help Reduce Medical Expenditure: Report
December 21, 2016
- Keytruda Gets NSCLC Nod Both in 1st-Line, 2nd-Line Settings
December 20, 2016
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…